Drugs / Batefenterol
Batefenterol
also known as
GSK961081 · BAT · BATEFENTEROL SUCCINATE · GSK-961081A · GSK-961081D · GSK961081 succinate · GSK961081edisylate · TD-5959
Small molecule targets ADRB2, CHRM2, CHRM3 via activation / inhibition
Trials 12
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Batefenterol | “The study aim was to investigate the pharmacokinetics of single high doses and repeated therapeutic doses of fluticasone furoate (FF) and batefenterol (BAT; a bifunctional...” PMID 30070770 ↗ Aug 20183“Batefenterol (GSK961081) is a bifunctional bronchodilator that is being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD).” NCT02663089 ↗ |
| Known as | BAT | “The study aim was to investigate the pharmacokinetics of single high doses and repeated therapeutic doses of fluticasone furoate (FF) and batefenterol (BAT; a bifunctional...” PMID 30070770 ↗ Aug 2018 |
| Known as | BATEFENTEROL SUCCINATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039518 ↗ |
| Known as | GSK-961081A | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039518 ↗ |
| Known as | GSK-961081D | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039518 ↗ |
| Known as | GSK961081 | “Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)” NCT02570165 ↗ |
| Known as | GSK961081 succinate | “The subjects will receive 1500 micrograms of GSK961081edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.” NCT00550225 ↗ |
| Known as | GSK961081edisylate | “The subjects will receive 1500 micrograms of GSK961081edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.” NCT00550225 ↗ |
| Known as | TD-5959 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039518 ↗ |
| Action | Activate | “Beta-2 adrenergic receptor agonist” CHEMBL3039518 ↗ |
| Action | Inhibit | “Muscarinic acetylcholine receptor M2 antagonist” CHEMBL3039518 ↗1“Muscarinic acetylcholine receptor M3 antagonist” CHEMBL3039518 ↗ |
| Modality | Other / unclassified | “batefenterol (BAT; a bifunctional muscarinic antagonist and β2 -agonist)” PMID 30070770 ↗ Aug 2018 |
| Modality | Small molecule | — CHEMBL3039518 ↗ |
| Route | Inhaled | “14 days dosing with inhaled GSK961081 DPI” NCT00478738 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor agonist” CHEMBL3039518 ↗ |
| Target | CHRM2 | “Muscarinic acetylcholine receptor M2 antagonist” CHEMBL3039518 ↗ |
| Target | CHRM3 | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL3039518 ↗ |